NATERA INC

NASDAQ: NTRA (Natera, Inc.)

Last update: 4 days ago, 8:18AM

161.76

0.19 (0.12%)

Previous Close 161.57
Open 161.73
Volume 468,868
Avg. Volume (3M) 1,312,006
Market Cap 22,087,843,840
Price / Sales 11.33
Price / Book 17.82
52 Weeks Range
92.14 (-43%) — 183.00 (13%)
Earnings Date 7 Aug 2025
Profit Margin -10.36%
Operating Margin (TTM) -15.78%
Diluted EPS (TTM) -1.47
Quarterly Revenue Growth (YOY) 36.50%
Total Debt/Equity (MRQ) 15.78%
Current Ratio (MRQ) 3.87
Operating Cash Flow (TTM) 153.12 M
Levered Free Cash Flow (TTM) 120.93 M
Return on Assets (TTM) -8.87%
Return on Equity (TTM) -18.66%

Market Trend

Short Term Medium Term
Industry Diagnostics & Research (US) Mixed Mixed
Diagnostics & Research (Global) Mixed Mixed
Stock Natera, Inc. Bullish Bullish

AIStockmoo Score

2.4
Analyst Consensus 4.0
Insider Activity 3.0
Price Volatility 2.0
Technical Moving Averages 3.5
Technical Oscillators -0.5
Average 2.40

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
NTRA 22 B - - 17.82
IDXX 41 B - 47.56 29.50
ILMN 16 B - - 6.71
ICLR 10 B - 14.19 1.26
EXAS 10 B - - 4.13
MEDP 9 B - 24.58 15.44

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier’s children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Sector Healthcare
Industry Diagnostics & Research
Investment Style Mid Growth
% Held by Insiders 3.24%
% Held by Institutions 96.37%

Ownership

Name Date Shares Held
Duquesne Family Office Llc 31 Mar 2025 3,402,330
52 Weeks Range
92.14 (-43%) — 183.00 (13%)
Price Target Range
190.00 (17%) — 218.00 (34%)
High 218.00 (UBS, 34.77%) Buy
Median 210.00 (29.82%)
Low 190.00 (Barclays, 17.46%) Buy
Average 206.00 (27.35%)
Total 3 Buy
Avg. Price @ Call 151.10
Firm Date Target Price Call Price @ Call
Piper Sandler 15 May 2025 210.00 (29.82%) Buy 149.40
Barclays 09 May 2025 190.00 (17.46%) Buy 151.95
10 Apr 2025 160.00 (-1.09%) Buy 143.28
UBS 09 May 2025 218.00 (34.77%) Buy 151.95
Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
BAYNES ROY D. 167.96 - 2,143 359,938
BERTAGNOLLI MONICA 167.96 - 2,143 359,938
BOTHA ROELOF 167.96 - 2,414 405,455
MARCUS GAIL BOXER 167.96 - 2,414 405,455
ROSENMAN HERM 167.96 - 2,414 405,455
WILLIAMS BRINKLEY RUTH 167.96 - 2,143 359,938
Aggregate Net Quantity 13,671
Aggregate Net Value ($) 2,296,181
Aggregate Avg. Buy ($) 167.96
Aggregate Avg. Sell ($) -
Name Holder Date Type Quantity Price Value ($)
BAYNES ROY D. Director 27 Jun 2025 Acquired (+) 2,143 167.96 359,938
BOTHA ROELOF Director 27 Jun 2025 Acquired (+) 2,414 167.96 405,455
BERTAGNOLLI MONICA Director 27 Jun 2025 Acquired (+) 2,143 167.96 359,938
WILLIAMS BRINKLEY RUTH Director 27 Jun 2025 Acquired (+) 2,143 167.96 359,938
MARCUS GAIL BOXER Director 27 Jun 2025 Acquired (+) 2,414 167.96 405,455
ROSENMAN HERM Director 27 Jun 2025 Acquired (+) 2,414 167.96 405,455
Date Type Details
07 Jul 2025 Announcement Natera Presents Data at ESMO GI on its Tissue-Free Latitude™ MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer
01 Jul 2025 Announcement Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD
04 Jun 2025 Announcement Natera Announces Medicare Coverage for Signatera™ Genome
02 Jun 2025 Announcement SignateraTM Genome Clinical Performance Highlighted at ASCO 2025
22 May 2025 Announcement Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting
08 May 2025 Announcement Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress
08 May 2025 Announcement Natera Reports First Quarter 2025 Financial Results
07 May 2025 Announcement Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows
05 May 2025 Announcement Largest Sarcoma Study to Date with ctDNA Analysis Demonstrates Excellent Performance for Signatera
01 May 2025 Announcement Natera to Report its First Quarter Results on May 8, 2025
01 May 2025 Announcement Notice to Shareholders of Natera, Inc. (NTRA) Regarding Dismissal of Putative Investor Class Action
29 Apr 2025 Announcement Prospective DEFINE-HT Study Demonstrates that Prospera™ Heart is Predictive of Clinical Outcomes and Outperforms Biopsy in Predicting Graft Dysfunction
24 Apr 2025 Announcement Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera™ Genome MRD Test
22 Apr 2025 Announcement Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria